Regeneron Pharmaceuticals (REGN) Cash from Operations (2009 - 2026)

Regeneron Pharmaceuticals' Cash from Operations history runs 18 years deep, the most recent figure standing at 1078900000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations rose 3.23% year-over-year to 1078900000.0 in Q1 2026; TTM through Mar 2026 was 5012700000.0, a 26.8% increase from a year earlier, with the FY2025 full-year figure at 4978900000.0, up 12.63% from the prior year.
• Cash from Operations fell to 1078900000.0 in Q1 2026 per REGN's latest filing, from 1170700000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 2101700000.0 in Q1 2022 and bottomed at 354000000.0 in Q2 2024.
• The 5-year median for Cash from Operations is 1144400000.0 (2025), against an average of 1181600000.0.
• Across the five-year window, Cash from Operations tumbled 81.58% in 2022 and surged 223.28% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 1719900000.0 in 2022, then tumbled by 36.64% to 1089700000.0 in 2023, then gained by 15.89% to 1262800000.0 in 2024, then retreated by 7.29% to 1170700000.0 in 2025, then fell by 7.84% to 1078900000.0 in 2026.
• Per Business Quant, the three latest REGN Cash from Operations figures stand at 1078900000.0 (Q1 2026), 1170700000.0 (Q4 2025), and 1618700000.0 (Q3 2025).